Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이희성 | * |
dc.date.accessioned | 2021-11-10T16:31:13Z | - |
dc.date.available | 2021-11-10T16:31:13Z | - |
dc.date.issued | 2021 | * |
dc.identifier.issn | 0028-3835 | * |
dc.identifier.other | OAK-30046 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/259366 | - |
dc.description.abstract | Introduction: The prognostic factors of pancreatic neuroendocrine tumor (PNET) are unclear, and the treatment guidelines are insufficient. This study aimed to suggest a treatment algorithm for PNET based on risk factors for recurrence in a large cohort. Methods: Data of 918 patients who underwent curative intent surgery for PNET were collected from 14 tertiary centers. Risk factors for recurrence and survival analyses were performed. Results: The 5-year disease-free survival (DFS) rate was 86.5%. Risk factors for recurrence included margin status (R1, hazard ratio [HR] 2.438; R2, HR 3.721), 2010 WHO grade (G2, HR 3.864; G3, HR 7.352), and N category (N1, HR 2.273). A size of 2 cm was significant in the univariate analysis (HR 8.511) but not in the multivariate analysis (p = 0.407). Tumor size was not a risk factor for recurrence, but strongly reflected 2010 WHO grade and lymph node (LN) status. Tumors ≤2 cm had lower 2010 WHO grade, less LN metastasis (p < 0.001), and significantly longer 5-year DFS (77.9 vs. 98.2%, p < 0.001) than tumors >2 cm. The clinicopathologic features of tumors <1 and 1-2 cm were similar. However, the LN metastasis rate was 10.3% in 1-2-cm sized tumors and recurrence occurred in 3.0%. Tumors <1 cm in size did not have any LN metastasis or recurrence. Discussion/Conclusion: Radical surgery is needed in suspected LN metastasis or G3 PNET or tumors >2 cm. Surveillance for <1-cm PNETs should be sufficient. Tumors sized 1-2 cm require limited surgery with LN resection, but should be converted to radical surgery in cases of doubtful margins or LN metastasis. © 2020 S. Karger AG, Basel. | * |
dc.language | English | * |
dc.publisher | S. Karger AG | * |
dc.subject | Neuroendocrine tumor | * |
dc.subject | Pancreas | * |
dc.subject | Recurrence | * |
dc.subject | Risk factor | * |
dc.subject | Treatment algorithm | * |
dc.title | Risk Factors for Recurrence in Pancreatic Neuroendocrine Tumor and Size as a Surrogate in Determining the Treatment Strategy: A Korean Nationwide Study | * |
dc.type | Article | * |
dc.relation.issue | 8 | * |
dc.relation.volume | 111 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 794 | * |
dc.relation.lastpage | 804 | * |
dc.relation.journaltitle | Neuroendocrinology | * |
dc.identifier.doi | 10.1159/000511875 | * |
dc.identifier.wosid | WOS:000681678800010 | * |
dc.identifier.scopusid | 2-s2.0-85112246633 | * |
dc.author.google | Kwon W. | * |
dc.author.google | Jang J.-Y. | * |
dc.author.google | Song K.B. | * |
dc.author.google | Hwang D.W. | * |
dc.author.google | Kim S.C. | * |
dc.author.google | Heo J.S. | * |
dc.author.google | Choi D.W. | * |
dc.author.google | Hwang H.K. | * |
dc.author.google | Kang C.M. | * |
dc.author.google | Yoon Y.-S. | * |
dc.author.google | Han H.-S. | * |
dc.author.google | Park J.S. | * |
dc.author.google | Hong T.H. | * |
dc.author.google | Cho C.K. | * |
dc.author.google | Ahn K.S. | * |
dc.author.google | Lee H. | * |
dc.author.google | Lee S.E. | * |
dc.author.google | Jeong C.-Y. | * |
dc.author.google | Roh Y.H. | * |
dc.author.google | Kim H.J. | * |
dc.author.google | Choi S. | * |
dc.author.google | Kim S.-W. | * |
dc.author.google | Lee W.J. | * |
dc.author.google | Han I.W. | * |
dc.author.google | Yoon D.S. | * |
dc.author.google | Kang K.J. | * |
dc.author.google | Min S.K. | * |
dc.author.google | Lee H.K. | * |
dc.author.google | Hong S.C. | * |
dc.contributor.scopusid | 이희성(56019344700) | * |
dc.date.modifydate | 20240501081003 | * |